MedTrace Logo

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

NCT07130903 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-11-10

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is:

* Effective in improving survival
* safe and tolerable

Conditions

  • Metastatic Colorectal Adenocarcinoma

Interventions

DRUG

Fruquintinib

Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class

DEVICE

TheraBionic P1

TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device

Sponsors & Collaborators

  • THERABIONIC INC.

    collaborator OTHER

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Mohammed Najeeb Al Hallak, MD · Wayne State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2028-04-17
Completion
2030-04-17
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07130903 on ClinicalTrials.gov